Fludarabine and Rituximab for the Treatment of Marginal Zone Non-Hodgkin's Lymphoma
Status:
Completed
Trial end date:
2012-01-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine the effectiveness of six cycles of concurrent
fludarabine and rituximab in patients with mucosa-associated lymphoid tissue (MALT) lymphoma,
marginal zone lymphoma (MZL) or CD5-, CD10-, CD20+ low-grade B cell lymphomas.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Biogen Genentech, Inc. Massachusetts General Hospital University of Rochester